IP Library Granted Patent US 10,918,633
Granted Patent B2
US 10,918,633 · App. 16/792,492 · Granted Feb 16, 2021

Method of treating coronavirus

Inventor: Jonnie R. Williams (Sarasota, FL)
Assignee: MyMD Pharmaceuticals, Inc.
A61K31/465A61K8/4926A61K31/4439A61P3/08C07K14/4747Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,918,633
App. No.
16/792,492
Granted
Feb 16, 2021
Kind
B2
Abstract

In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.

Claims (7)

1. A method of modulating an anti-inflammatory counteractive response characterized by release of cytokines in an individual suffering from a viral infection, the method comprising administering to the individual a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

2. The method of claim 1 , wherein the viral infection is Th1-mediated, and the anti-inflammatory counteractive response is characterized by release of Th-2-type cytokines.

3. The method of claim 2 , wherein a virus causing the Th1-mediated viral infection causes a respiratory disorder.

4. The method of claim 1 , wherein the therapeutically effective amount is from about 0.01 to about 50 mg/kg/day.

5. The method of claim 1 , wherein the therapeutically effective amount is from about 0.1 to about 25 mg/kg/day.

6. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 10 mg/kg/day.

7. The method of claim 1 , wherein the pharmaceutically acceptable salt is isomyosmine hydrochloride.

Assignments (4)
CHANGE OF NAME Recorded Jun 10, 2025
From: MYMD PHARMACEUTICALS, INC.
To: TNF PHARMACEUTICALS, INC.
Reel/Frame 071501/0834 →
MERGER Recorded Apr 22, 2022
From: MYMD PHARMACEUTICALS (FLORIDA), INC.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 059680/0941 →
CHANGE OF NAME Recorded Jun 25, 2021
From: MYMD PHARMACEUTICALS, INC.
To: MYMD PHARMACEUTICALS (FLORIDA), INC.
Reel/Frame 056670/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2020
From: WILLIAMS, JONNIE R.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 051831/0644 →
Continuity (4)
Continuation In Part 16791290 · Feb 14, 2020
Division 15558094
Provisional Application 62140618 · Mar 31, 2015
Related Publication 20200179367A1 · Jun 11, 2020
Cited By (1)
US 12,357,625